Your browser doesn't support javascript.
loading
Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke.
Kim, Yerim; Lee, Sang-Hwa; Kang, Min Kyoung; Kim, Tae Jung; Jeong, Han-Yeong; Lee, Eung-Joon; Bae, Jeonghoon; Jeon, Kipyoung; Nam, Ki-Woong; Yoon, Byung-Woo.
Afiliación
  • Kim Y; Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul 05355, Korea.
  • Lee SH; Department of Neurology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24253, Korea.
  • Kang MK; Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University College of Medicine, Uijeonbu-si 11759, Korea.
  • Kim TJ; Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.
  • Jeong HY; Emergency Medical Center, Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.
  • Lee EJ; Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.
  • Bae J; Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.
  • Jeon K; Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.
  • Nam KW; Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul 03080, Korea.
  • Yoon BW; Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University College of Medicine, Uijeonbu-si 11759, Korea.
Brain Sci ; 11(3)2021 Mar 06.
Article en En | MEDLINE | ID: mdl-33800924
ABSTRACT

Background:

There is growing interest in the use of new biomarkers such as glycated albumin (GA), but data are limited in acute ischemic stroke. We explored the impact of GA on short-term functional outcomes as measured using the modified Rankin Scale (mRS) at 3 months compared to glycated hemoglobin (HbA1c).

Methods:

A total of 1163 AIS patients from two hospitals between 2016 and 2019 were included. Patients were divided into two groups according to GA levels (GA < 16% versus GA ≥ 16%).

Results:

A total of 518 patients (44.5%) were included in the GA ≥ 16% group. After adjusting for multiple covariates, the higher GA group (GA ≥ 16%) had a 1.4-fold risk of having unfavorable mRS (95% CI 1.02-1.847). However, HbA1c was not significantly associated with 3-month mRS. In addition, GA ≥ 16% was independently associated with unfavorable short-term outcomes only in patients without diabetes.

Conclusions:

In light of these results, GA level might be a novel prognostic biomarker compared to HbA1c for short-term stroke outcome. Although the impact of GA is undervalued in the current stroke guidelines, GA monitoring should be considered in addition to HbA1c monitoring.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Brain Sci Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Brain Sci Año: 2021 Tipo del documento: Article
...